Norcantharimide analogues possessing terminal phosphate esters and their anti-cancer activity

Mark J. Robertson, Christopher P. Gordon, Jayne Gilbert, Adam McCluskey, Jennette A. Sakoff

    Research output: Contribution to journalArticlepeer-review

    26 Citations (Scopus)

    Abstract

    A family of norcantharidin analogues possessing a terminal alcohol (ethanol, propanol, butanol, pentanol, hexanol and cyclohexanol) moiety were treated with either chlorodiethyl, chlorodiphenyl or chloro-bis-trichloroethyl- phosphate to afford highly focused libraries of the corresponding phosphate esters. Subsequent biological screening against a panel of nine human cancer cell lines identified a trend between the ease of phosphate unmasking (phosphate ester hydrolysis) and cell death. The most potent analogues possessed either a diphenyl or a bis-trichloroethyl moiety. The effect of alkyl spacer was also examined with the hexyl analogues typically more potent. 4-Aza-4-(3-{bis(2,2,2- trichloroethyl)phosphate}propyl)-10-oxatricyclo[5.2.1.0]decane-3,5-dione (10b) was the most potent analogue synthesised with an average GI 50 of 11 μM across a panel of nine human carcinoma cell lines: colon carcinoma (HT29 and SW480); breast carcinoma (MCF-7); ovarian carcinoma (A2780); lung carcinoma (H460); skin carcinoma (A431); prostate carcinoma (DU145); neuronal carcinoma (BE2-C) and brain carcinoma (SJ-G2). This represents a fivefold improvement in anti-proliferative activity relative to the lead, norcantharidin.
    Original languageEnglish
    Pages (from-to)5734-5741
    Number of pages8
    JournalBioorganic and Medicinal Chemistry
    Volume19
    Issue number18
    DOIs
    Publication statusPublished - 2011

    Fingerprint

    Dive into the research topics of 'Norcantharimide analogues possessing terminal phosphate esters and their anti-cancer activity'. Together they form a unique fingerprint.

    Cite this